Advanced Filters
noise
Found 842 clinical trials
R Robert Lynn

Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease

This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.

45 - 80 years of age All Phase 1
S Sigrid Botne Sando, MD, PhD

Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease

Introduction Given that exercise training reduces the risk of developing Alzheimer's disease (AD), induces changes in the blood composition and has widespread systemic benefits, it is reasonable to hypothesize that exercised plasma may have rejuvenative properties. The main objective is to test safety and tolerability of transfusing exercised plasma (ExPlas) …

50 - 75 years of age All Phase 2

Effectiveness of a High-intensity Interval Exercise Program in People With Alzheimer's

Alzheimer's disease (AD) is a the most common type of dementia. It is a progressive disease that affects different areas of human behavior at the cognitive, social, physical and metabolic levels. The benefits of a High-Intensity Interval Exercise Program (HIIT) has been proven not only in healthy older adults, but …

60 - 90 years of age All Phase N/A
E Elaina Niciforos

Cannabidiol Medication Intervention Trial

CALM-IT is a Randomized, double-blind, placebo-controlled cross-over clinical trial. Safety and efficacy of cannabidiol (CBD) capsules assessed for managing agitation in patients with AD and to identify novel biomarkers of agitation severity and treatment response.

55 years of age All Phase 2
D Diana S. Guzman

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, …

50 years of age All Phase 2
E Eva Wu

Gamma-Music Based Intervention for Mild Alzheimer's Disease

The study will test and refine a novel brain-stimulation tool using gamma-frequency lights coupled with self-selected music for a gamma-music-based intervention for participants with mild Alzheimer's Disease. Results will yield a gamma-stimulation protocol that reliably influences brain activity (Aim 1), is adaptive, motivating and rewarding to use (Aim 2), and …

50 - 95 years of age All Phase N/A
A Andre Guthrie, BS, CCRP

R21 Roche: 3-Way Tau Tracers in AD

This is an open label study to compare three new generation TAU radioligands, 18F-RO948 (formerly known as 18F-6958948), 18F-MK6240, and [18F]GTP1for imaging of taupathy and demonstrate their absence of off-target binding in patients with Alzheimer disease (AD) and older healthy controls (OC). The study will directly compare AD and OC …

50 - 100 years of age All Phase 1

Effect of CAFfeine on Cognition in Alzheimer's Disease

Sporadic Alzheimer's disease is a multifactorial illness arising a major medico-economic stakes for our aging societies. There is currently no curative treatment available. Coffee is a complex beverage with psychostimulant properties whose main effective element, caffeine, has a pleiotropic effect on the central nervous system. Caffeine pharmacological properties enable its …

50 years of age All Phase 3
J Julien DELRIEU, Neurologist-Geriatrician

Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease

This is a controlled investigation, with randomization of the patients, which aims at demonstrating the efficacy of device RGn600 in treating patients with mild-to-moderate Alzheimer's disease (AD). RGn600 is a non-invasive medical device which is applied on the head (helmet) and on the abdomen (abdominal belt). It combines 2 technologies: …

55 - 85 years of age All Phase N/A
A April Riddle, BSRT

UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451 in the brain will be correlated to demographic, clinical, genetic, and biospecimen data …

50 years of age All Phase 1

Simplify language using AI